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OBJECTIVES We evaluated the role of Cypher/ZASP in the pathogenesis of dilated cardiomyopathy (DCM)
with or without isolated non-compaction of the left ventricular myocardium (INLVM).
BACKGROUND Dilated cardiomyopathy, characterized by left ventricular dilation and systolic dysfunction
with signs of heart failure, is genetically transmitted in 30% to 40% of cases. Genetic
heterogeneity has been identified with mutations in multiple cytoskeletal and sarcomeric
genes causing the phenotype. In addition, INLVM with a hypertrophic dilated left ventricle,
ventricular dysfunction, and deep trabeculations, is also inherited, and the genes identified to
date differ from those causing DCM. Cypher/ZASP is a newly identified gene encoding a
protein that is a component of the Z-line in both skeletal and cardiac muscle.
METHODS Diagnosis of DCM was performed by echocardiogram, electrocardiogram, and physical
examination. In addition, levels of the muscular isoform of creatine kinase were measured to
evaluate for skeletal muscle involvement. Cypher/ZASP was screened by denaturing high
performance liquid chromatography (DHPLC) and direct deoxyribonucleic acid sequencing.
RESULTS We identified and screened 100 probands with left ventricular dysfunction. Five mutations in
six probands (6% of cases) were identified in patients with familial or sporadic DCM or
INLVM. In vitro studies showed cytoskeleton disarray in cells transfected with mutated
Cypher/ZASP.
CONCLUSIONS These data suggest that mutated Cypher/ZASP can cause DCM and INLVM and identify a
mechanistic basis. (J Am Coll Cardiol 2003;42:2014–27) © 2003 by the American College
of Cardiology Foundation
Dilated cardiomyopathy (DCM) is a primary heart muscle
disease characterized by left ventricular dilation, systolic
dysfunction, secondary diastolic dysfunction, and is occa-
sionally associated right ventricular disease (1). A major
cause of morbidity and mortality, DCM is the most com-
mon cause of congestive heart failure. This disorder affects
40 in every 100,000 of the population (2), often necessitat-
ing cardiac transplantation, with an estimated cost of $10 to
$40 billion yearly in the U.S. (2). Depending on the
diagnostic criteria used, the annual incidence ranges from 5
to 8 cases per 100,000 population (2,3), but the true
incidence is probably higher as many asymptomatic cases go
unrecognized.
The underlying causes of DCM are heterogeneous (4,5),
including myocarditis, alcohol abuse, drug toxicity (such as
adriamycin), and ischemia-induced, metabolic, and genetic
abnormalities. In 30% to 40% of cases (6–8), DCM is a
familial disease with a high level of heterogeneity. Autoso-
mal dominant inheritance of DCM is the most common
(5), with two main forms described as: 1) “pure” DCM, and
2) DCM associated with cardiac conduction system disease
(CDDC) (9). Multiple genetic loci have been identified for
autosomal dominant DCM, with mutations being identified
in actin (10), desmin (11), lamin A/C (12), -sarcoglycan
(13), -sarcoglycan (14), -myosin heavy chain (15), car-
diac troponin T (15), -tropomyosin (16), titin (17,18),
vinculin (19), muscle LIM protein (20), and phospholam-
ban (21,22). In addition, mutations in taffazzin (G4.5) cause
DCM with endocardial fibroelastosis in patients with the
Barth syndrome (23) or isolated non-compaction of the left
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ventricular myocardium (INLVM) (24), a disorder in which
a dilated hypertrophic left ventricle with poor systolic
function and deep trabeculations is notable (25). This
phenotype, which is also known as left ventricular non-
compaction (LVNC), is thought to occur because of ar-
rested myocardial development. It has been reported to
occur in isolation (frequently due to G4.5 mutations) or in
association with congenital heart disease. In the latter case,
mutations in -dystrobrevin have been reported (24).
We have previously proposed that DCM results from
mutations that affect elements of the cytoarchitecture that
connect the extracellular matrix to the nucleus through the
sarcolemma, the dystrophin-associated glycoprotein com-
plex, dystrophin, the cytoskeleton, the contractile apparatus,
and the intermediate filaments (26). This has been sup-
ported by the genes identified for human forms of DCM to
date, as well as animal models. A novel gene within this
pathway, shown to result in cardiomyopathy in knockout
mice, is a Z-band complex-encoding gene called Cypher
(27). The characterization of the human gene, known as the
Z-band alternatively spliced PDZ-motif protein (ZASP)
(28), and analysis for mutations in patients with DCM or
LVNC are reported here.
METHODS
Patient evaluation. All patients were evaluated by physical
examination (particularly focused on the cardiac and neu-
romuscular systems), chest radiography, electrocardiogra-
phy, echocardiography, and magnetic resonance imaging
(MRI). Left ventricular size and function were evaluated by
M-mode and two-dimensional Doppler and color Doppler
echocardiographic images, as previously described (13).
Serum creatine kinase levels were measured to evaluate the
patients for the presence of skeletal myopathy.
After informed consent, blood for lymphoblastoid cell
line immortalization and deoxyribonucleic acid (DNA)
extraction (13) was obtained, as regulated by the Baylor
College of Medicine Institutional Review Board.
Characterization of ZASP genomic structure. The bac-
terial artificial chromosomes (BACs) encoding the Cypher/
ZASP gene were identified by hybridization of a human
BAC filter library (RPCI-11, Roswell Park Cancer Insti-
tute, Buffalo, New York) with overrun probes followed by
direct DNA sequencing of BAC DNA, using an ABI 310
(Applied Biosystems, Foster City, California) and Big Dye
Terminator chemistry, according to the manufacturer’s
instructions.
Denaturing high performance liquid chromatography
(DHPLC) and DNA sequence analysis. Genomic DNA
samples were amplified by polymerase chain reaction (PCR)
using primers designed to amplify the Cypher/ZASP gene in
an exon-by-exon manner (Table 1) and analyzed by DH-
PLC, using a WAVE DNA Fragment Analysis System
(Transgenomic, Omaha, Nebraska), as previously described
(29). When an abnormal DHPLC peak was detected, the
genomic DNA was re-amplified, and the PCR product
purified, using the QIAquick PCR Purification Kit (Qia-
gen, Stanford, California), and sequenced, using an ABI
3100 (Applied Biosystems) and Big Dye Terminator chem-
istry as described in the previous text.
Expression analysis. We investigated the cardiac expres-
sion in humans of Cypher/ZASP isoforms by reverse tran-
scription (RT)-PCR from total human heart messenger
ribonucleic acid (mRNA) (Clontech, Palo Alto, California).
The RT was performed as previously described (13). The
PCR was carried out using the following primers: exon 2F
(5-ATCACACCAGGCAGCAAGG-3) and exon 2R
(5-CTGCAGGGTGAGGCTCAAGT-3), which am-
plify a 152 bp PCR product from all isoforms; exon 4F
(5-ACCTTTAGCCCTGCCTTCTC-3) and exon 4R
(5-AGGGTCTCTGCCGAGTACAG-3), which gen-
erate a 200 bp product from Cypher/ZASP4-6; exon 10F
(5-CACCTGCTGCTGCCTCTC-3) and exon 10R
(5-GTCGGCAGGACTTGAAGC-3), which generate
a 110 bp PCR product from the Cypher/ZASP2 and -4
isoforms; exon 5F (5-GTAGTCAACTCTCCAGCCA-
3) and exon 6R (5-ATGATGGCATCCTGGGAATA-
3), which amplify a 176 bp product from the Cypher/
ZASP1, -2, and -3 isoforms; and exon 7F (5-
AAGGACCTTGCCGTAGACAG-3) and exon 7R (5-
AATTCTGTCCCCGTCATCTG-3), which amplify a
155 bp PCR product from all Cypher/ZASP isoforms.
Primers to amplify the glucose-6-phosphate mRNA were
used as positive controls (30), whereas RT reactions lacking
reverse transcriptase were performed as negative controls.
The PCR was performed in a 30 l reaction containing
1.5 mmol/l MgCl2, 10 pmol of each primer, 200 mol/l
dNTP, and 0.5 U platinum Taq DNA polymerase (Invitro-
gen, Carlsbad, California), using a Stratagene Robocyler.
Following a 5-min denaturation step at 94°C, 35 rounds of
amplification (94°C for 30 s, 54°C to 60°C for 30 s, 72°C for
20 s) were performed. This was followed by a 72°C
incubation for 2 min. The PCR products were analyzed by
2% agarose gel electrophoresis. All RT-PCR products were
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sequenced to confirm their identity, cloned in pCR2.1-
TOPO (Invitrogen), and used as probes for Northern blot
analysis (see the following text).
Northern blot analysis. A total of 15 g of isolated total
human heart ribonucleic acid (RNA) (Ambion, Austin,
Texas) was denatured in a formamide/formaldehyde solu-
tion at 68°C for 10 min and samples were resolved on 1%
denaturing agarose gel electrophoresis. The gel was stained
with ethidium bromide solution and photographed; after
washing, the RNA was transferred to a Hybond-N nylon
membrane (Amersham Bioscience, Piscataway, New Jer-
sey). After ultraviolet cross-linking, blots were pre-
hybridized in a buffer containing 50 mmol/l piperazine-
N,N-bis (2-ethenesulfonic acid), 100 mmol/l NaCl, 50
mmol/l sodium phosphate (pH 7.0), 1 mmol/l
ethylenediamine-tetraacetic acid, and 5% sodium dodecyl
sulfate (SDS) at 55°C for 30 min. Cloned complementary
DNA probes were radiolabeled with [-32P] deoxycytidine
triphosphate (3,000 Ci/mmol) (Amersham Bioscience), and
added to the pre-hybridization solution. The membranes
were hybridized for 16 h at 65°C, then washed in 1
standard saline citrate containing 5% SDS at 55°C for 30
min, and exposed to X-ray film at 80°C.
Site-directed mutagenesis. The Cypher/ZASP D117N
mutant was prepared using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, California) employ-
ing the plasmid plasmid cDNA 3.1(-)-Cypher/ZASP-WT,
which contains the open reading frame of Cypher/ZASP1
cloned into the BamHI and HindIII restriction sites of the
pcDNA 3.1(-) vector (Invitrogen), as a template. The follow-
ing primers were used: 117-F (5-CCAGCCAACGCCAAC-
TACCAGGAACGC-3) and 117-R (5-GCGTT-
CCTGGTAGTTGGCGTTGGCTGG-3). The PCR was
performed with 10 ng of template DNA in a 50 l reaction
containing 200 nmol/l of each primer, 200 mol/l of dNTP
mix, 2.5 U of Pfu Turbo DNA polymerase (Stratagene), and
15 rounds of amplification (95°C for 30 s, 55°C for 1 min,
68°C for 12.5 min). Subsequently, the PCR product was
incubated at 37°C for 1 h with 10 U of Dpn I, and 5 l were
used to transform XL1-blue Supercompetent cells (Invitro-
gen). The mutated Cypher/ZASP clones were sequenced to
ensure the presence of the D117N mutation, as well as the
Table 1. Primers Used for the Screening of the Cypher/ZASP Gene
Exon Primer Primer Sequence (5-3) TA* (°C)
PCR Product
Size (bp)
1 ZASP 1F GTGCCCTCTCACTCAACCCT 62 221
ZASP 1R ACACATGCCCTCCTCCAAGC
2 ZASP 2F TGGCCTTTCCTCAGGACCAC 56 335
ZASP 2R TCCTGCACAGTTTTGTAGCC
3 ZASP 3F TGACTCTGGCTCTCTCTTGCT 54 230
ZASP 3R TCCAGGAACCAGGGCTGAGT
4 ZASP 4F GGCTCGCGCTAACACATCTG 58 506
ZASP 4R GCCACCTGTGGAGAGCTGTA
5 ZASP 5F CACTCCTTGCTCTCCTCACC 60 266
ZASP 5R CTCTATCCACGCCAGACACA
6 ZASP 6F TGTAACCGCCACCTGTTGCC 58 380
ZASP 6R TCCAGGAGGTCCAACGTGAG
7 ZASP 7F CCACCAATGGGCATGGAGCA 55 353
ZASP 7R AGCAGGACTCCCTGGCTTCT
8 ZASP 8F TTGCTGTGTCTCCCGTGAGT 56 178
ZASP 8R GAGGTCCCTTCCATGAGTGA
9 ZASP 9F GGTGAACACATTCCCTAACC 54 317
ZASP 9R CCCAGCAGAGTTATACATTG
10 ZASP 10F GCTCCCTTGACCTGTTGTCT 64 331
ZASP 10R GCCCTAACTACCTTGGACAC
11 ZASP 11F GGCTGTCCTTCTGGGTGTAA 54 257
ZASP 11R TCTTGGCTCTTGTGGCTCCT
12A ZASP 12AF CATTTCTCTGGCTAGGAGTG 58 348
ZASP 12AR CTGGGAGAAGCTATCATCTG
12B ZASP 12BF TGCACCCTCGGTGGCCTACA 58 352
ZASP 12BR CTCCCAACCAGGGCTCAGAC
13 ZASP 13F GTTCTGGGAGCTGCCTTACT 54 267
ZASP 13R GGAAGAGACATGGGTCAGAG
14 ZASP 14F AGTCAAGCCCGCTCCCTCTC 55 200
ZASP 14R CACATGCCATCGAAGTGTTC
15 ZASP 15F TGATTTGGGGTTTGTCTTGG 53 290
ZASP 15R CTAGCGTGGCAAGGTATGTA
16 ZASP 16F GTCTCACGCAGGTCTGTTCT 53 229
ZASP 16R GCTTCCTCTCTCTCCCCATT
*TA is the annealing temperature used in the polymerase chain reactions (PCR) reactions.
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absence of other substitutions introduced by the DNA poly-
merase. The wild-type and mutated Cypher/ZASP inserts were
then sub-cloned by PCR into the pcDNA 3.1/NT-GFP-
TOPO vector (Invitrogen) and re-sequenced.
Mammalian cell transfection and immunohistochemistry.
Transient transfections of the skeletal myoblast cell line
C2C12 with the wild-type and mutant pcDNA 3.1(-)-
Cypher/ZASP or pcDNA 3.1/NT-GFP-TOPO-Cypher/
ZASP constructs were performed using Lipofectamine Plus
(Invitrogen), according to the manufacturer’s instructions.
Cells were maintained in growth medium containing 10%
fetal calf serum (Invitrogen) for 24 h post-transfection.
Cypher/ZASP-GFP fusion proteins were detected in
transfected cells by washing with 1 phosphate-buffered
saline, fixation with a 70% acetone:30% ethanol solution at
20°C for 30 min, followed by incubation for 45 min with
1.5 mol/l tetrarhodamine isothioxyanate-labeled phalloi-
din (Molecular Probes, Eugene, Oregon) and (4,6-
diamidino-2-phenylindole (Molecular Probes) for actin fil-
ament and nuclear staining, respectively, while green
fluorescence protein (GFP) fluorescence was detected di-
rectly. Fluorescence was visualized as previously described
(22,31).
Western blot analysis. The C2C12 cells transfected with
wt-Cypher/ZASP, and D117N-Cypher/ZASP were har-
vested 24 h post-transfection and washed three times in
phosphate-buffered saline. After sedimentation by centrif-
ugation (1,000  g, 5 min) the cells were soaked in 500 l
of hypotonic buffer (1 mmol/l NaHCO2) containing 2
mmol/l phenylmethyl myeloid fluoride and 1 g/ml of
aprotinin, and lysed by three cycles of freeze and thaw.
Proteins were separated into soluble and insoluble fraction
by centrifugation at 15,000 g for 10 min. The supernatants
were mixed with 0.5 volumes of 3 loading buffer (30%
glycerol, 6% SDS, 62.5 mmol/l Tris-base-hydrochloric acid
buffer, pH 6.8). The pellet was re-suspended in 750 l of
1 loading buffer (10% glycerol, 2% SDS, 62.5 mmol/l
Tris-base-hydrochloric acid buffer, pH 6.8) and then clari-
fied by centrifugation at 15,000 g for 15 min.
After dilution in Laemmli sample buffer (Bio-Rad, Her-
cules, California) and heating to 100°C for 5 min, 30 g of
protein were loaded per lane. Proteins were separated on a
3% to 8% NuPage Tris-acetate polyacrylamide gel (Invitro-
gen) at 150 V for 1 h, and then transferred to nitrocellulose
membranes by electrotransfer at 21 V for 18 h at 4°C.
Cypher/ZASP was detected using a 1:2,000 dilution of a
mouse polyclonal anti-Cypher/ZASP antibody (28), followed
by staining with horseradish peroxidase-labeled anti-mouse
secondary antibody (Santa Cruz Biotechnology, Santa Cruz,
California) and chemiluminescent detection using an enhanced
chemiluminescence kit (Amersham-Biosciences).
RESULTS
Clinical evaluation. A total of 100 probands (69 Cauca-
sian, 14 African-American, 13 Hispanic, 4 Asian) were
identified by standard clinical evaluation after presenting
with features of heart failure (n  91) or sudden death (n 
9). In all living cases, diagnostic criteria included a dilated
left ventricular end-diastolic dimension and reduced systolic
function using ejection fraction or fractional shortening
measurements, with or without other features including
trabeculation of the left ventricular myocardium consistent
with INLVM, identified in 15 of the 100 probands (15%).
All probands were classified as New York Heart Association
(NYHA) functional class II to IV at the time of diagnosis.
In all autopsy cases, evidence of left ventricular dilation,
increased heart weight, and gross and anatomic features
consistent with DCM or INLVM were used for diagnosis.
Evaluation of family history, as well as echocardiographic
or MRI evaluation of relatives of the probands, identified 31
familial cases (defined as two or more affected individuals)
and 69 sporadic cases. Creatine kinase levels were normal in
all the probands or affected family members identified as
mutation carriers, and there was no clinical evidence of
skeletal myopathy.
Molecular analysis: genomic structure and sequences.
Screening of a human BAC library identified two BACs
(BAC 659G15 and BAC 656A18) containing most of the
Cypher/ZASP coding sequence. Further alignments were
performed by BLAST search, which identified two over-
lapping human genome clones from chromosome 10,
namely RP11-41D8 and RP11-359E3 (GenBank accession
numbers AL391985 and ACO67750, respectively), con-
taining the entire Cypher/ZASP gene sequence.
The DNA sequence analysis identified 16 coding exons
spanning approximately 70 kb (Fig. 1A) (Table 2). Six
isoforms have been detected in human mRNA (Fig. 1A).
The PDZ domain, which is present in all Cypher/ZASP
isoforms, is encoded by exons 1 through 3, whereas exons 12
to 16 encode for the three LIM domains, which is shared by
four of the six isoforms (Fig. 1A).
Mutation analysis. Mutations in Cypher/ZASP were iden-
tified in 6 (6%) of the 100 probands. Mutations were
identified in two families (FDCM 066 and FDCM/
INLVM 065) and four sporadic cases (DCM/INLVM 035,
INLVM-11, INLVM-17, and DCM-31) (Figs. 2 to 5).
None of these mutations were identified in 200 ethnically
matched control individuals (400 chromosomes). The clin-
ical characteristics of these patients and families are shown
in Table 3.
All but one mutation identified in the Cypher/ZASP
gene resulted in amino acid changes in residues that are
conserved between different species, and all lie within the
linker between the PDZ and LIM domains of the Cypher/
ZASP protein (Fig. 1B). In addition, computer modeling of
Cypher/ZASP wild-type and mutant proteins, using the
PSIPRED V2.2 analysis software (32), predicted protein
secondary structure changes in each of the mutated proteins
(data not shown).
Familial DCM. FAMILY FDCM 066. An abnormal DHPLC
pattern was identified in exon 10 of Cypher/ZASP (Fig. 2A).
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Figure 1. Cypher/ZASP genomic structure. (A) Representation of the Cypher/ZASP genomic structure (top), and six messenger ribonucleic acid isoforms,
termed Cypher/ZASP-1, -2, -3, -4, -5, and -6. The PDZ domain is encoded by exons 1, 2, and 3; the three LIM domains are encoded by exons 12-16.
(B) The location of mutations identified in this study. Note that the mutation in C/Z1 will also be present in the C/Z2 and 3 isoform (not shown), and
the mutation in C/Z4 will also be present in C/Z5 and 6 isoform (not shown).
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Table 2. Exon/Intron Boundaries in Human Cypher/ZASP Gene
Exon Size Splice Acceptor* Splice Donor*†
1 172 . . .ttgtctgcagag GCGGCC TCCCGG gtgagtgcaccc. . .
2 152 . . .ctatccaatcag ATCACA GCAGAA gtaggtgggagc. . .
3 76 . . .tggtttctacag ATCAAA CAGAAG gtaggtgctgact. . .
4 368 . . .gccctgtgccag GACCCC AGGAGG gtaggtaacgg. . .
5 23 . . .ttcctccccag GTGGTA AGCCAA gttagtatcaa. . .
6 204 . . .cccctcccccag CGCCGA CAGTGG gtaagcgcctcc. . .
7 170 . . .tctgcattacag GAGCCT AATTCA gtgagtgcaggc. . .
8 37 . . .ttctaccaacag TGCAAG GTCAAG gtaagtgcctgg. . .
9 773 . . .tctgtgccacag GGAAAG AGCTAA. . .
10 189 . . .ccgcctcatcag CACCCC CCCAAG gtaactgggcca. . .
11 146 . . .gcttggttccag GCCCCA AGCCAG gtaagaggcaga. . .
12 445 . . .tggcttttgcag TGCCTG CATCCG gtatggtccagc. . .
13 181 . . .gtgcttccccag GGGCCC ATGGGG gtaagtgggagg
14 121 . . .tctttcccccag GAAGTA AGAAAG gtaggaacactt. . .
15 116 . . .ttttcatttcag ACTACA TGCGCA gtatgtctcta. . .
16 2110 . . .tctctgctccag GTCTGC TTGTAG. . .
*Exonic sequences are shown in bold upper case while intronic sequences are in lower case: concensus splice site sequences are
shown in bold. †For exons 9 and 16, the sequence at the termination codon is shown.
Figure 2. Mutation detection in FDCM 066. (A) Denaturing high performance liquid chromatography (DHPLC) of exon 10 identifies an abnormal
DHPLC pattern in the proband (top panel) that is absent in controls (bottom panel). (B) The deoxyribonucleic acid (DNA) sequence analysis of genomic
DNA identifies a C to G base substitution at position 1056. (C) Pedigree of family FDCM 066 showing the nucleotides identified at 1056. The arrow
identifies the proband.
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The DNA sequence analysis identified a single nucleotide
change, C1056G (Fig. 2B), which results in an amino acid
change from isoleucine to methionine at position 352
(I352M) in Cypher/ZASP4 (Fig. 1B). This amino acid
change is predicted to abolish an -helix and a short -sheet
in Cypher/ZASP 4 (data not shown). This family has pure
DCM and an inheritance pattern consistent with an
autosomal dominant trait (Fig. 2C). Analysis of the
Figure 3. Mutation detection in FDCM/INLVM 065. (A) Denaturing high performance liquid chromatography (DHPLC) analysis of exon 4 identifies
an abnormal DHPLC pattern in the proband (top panel) that is absent in controls (bottom panel). (B) The deoxyribonucleic acid (DNA) sequence analysis
of genomic DNA identifies a C to T base substitution at position 587. (C) Pedigree of family FDCM/INLVM 065. The arrow identifies the proband.
(D) Blast homology analysis of Cypher/ZASP amino acid sequence for residue S196.
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available family members showed that the affected indi-
viduals carried the same heterozygous mutation, while
unaffected family members did not. This residue does not
appear to be highly conserved, although the variant we
identified is not present in any species of Cypher/ZASP
so far characterized.
Figure 4. Mutation detection in DCM 035. (A) Denaturing high performance liquid chromatography (DHPLC) analysis of exon 4 identifies an abnormal
DHPLC pattern (top panel), which is absent in controls (bottom panel). (B) The deoxyribonucleic acid (DNA) sequence analysis of genomic DNA
identifies a C to T base substitution at position 638. (C) Blast homology analysis of Cypher/ZASP amino acid sequence for residue T213.
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FAMILY FDCM/INLVM 065. An abnormal DHPLC pattern
was identified in exon 4 of the proband (Fig. 3A). The
DNA sequence analysis identified a C587T missense mu-
tation (Fig. 3B) that leads to the substitution of serine 196
with a leucine (S196L) in Cypher/ZASP4 (Fig. 1B), result-
ing in the creation of a short -helix beginning at residue
175 of Cypher/ZASP4, whereas the -helix beginning at
residue 214 is predicted to be abolished (data not shown).
This residue is conserved in mouse and rat. The 40-year-old
proband of this family was diagnosed with DCM associated
with mild left ventricular hypertrophy and a trabeculated left
ventricular on echocardiogram. In this family, there are four
other affected individuals (Fig. 3C): individual I:2 is the
mother of the proband (a 68-year-old); individuals II:2 and
II:3 are the two brothers of the proband, one of which (II:2)
died with a severe dilated cardiomyopathy at 41 years of age;
and the living daughter (III:1) of the deceased brother, who
is 7 years old and presented with a mildly dilated left
ventricle. The mutation was only identified in affected
individuals; no DNA was available from the deceased
subject.
Sporadic DCM and INLVM. PATIENT DCM/INLVM
035. This sporadic DCM patient, a 15-month-old Latin
American male, was admitted to the hospital with profound
bradycardia, atrioventricular block, premature ventricular
contractions, monomorphic ventricular tachycardia, and
depressed ventricular function with mild left ventricular
dilation. During the subsequent three years of follow-up,
the patient significantly improved by echocardiographic
criteria, with only mild DCM currently noted. Screening of
the parents demonstrated normal left ventricular size and
function with no abnormalities on echocardiographic
analysis.
An abnormal DHPLC pattern was identified in exon 4
(Fig. 4A), resulting in a C to T substitution of nucleotide
638 (Fig. 4B). This changed the amino acid at codon 213
Figure 5. Mutations identified in INLVM-11, INLVM-17, and DCM-31. (A) The deoxyribonucleic acid (DNA) sequence analysis of exon 6 identifies
a G349A substitution in Patient INLVM-11. Note that the reverse sequence is shown. (B) The DNA sequence analysis of genomic DNA from Patient
DCM-31 identifies an A407T transversion. (C) Blast homology analysis of Cypher/ZASP amino acid sequence for residues D117 and K136.
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from the polar amino acid threonine to the non-polar amino
acid isoleucine (T213I) in Cypher/ZASP4 (Fig. 1B), result-
ing in the creation of two short -helices beginning at
residues 291 and 343, while a short -sheet was created at
residue 352 (data not shown). Threonine 213 is conserved
both in mouse and rat. Neither parent had this substitution.
PATIENTS INLVM-11 AND INLVM-17. Abnormal DHPLC
patterns were identified in exon 6 in the Caucasian patients
INLVM-11 and INLVM-17. The INLVM-11 is a 44-
year-old female, diagnosed at 41 years of age with sporadic
form of DCM, NYHA functional class III heart failure, left
bundle branch block on surface electrocardiogram, reduced
systolic function (fractional shortening 23%), dilated left
ventricular (5.9 cm), deep trabeculations, and reduced meta-
bolic exercise testing, with a maximum oxygen consumption of
58% predicted at 14 ml/kg/min. She is now stabilized (NYHA
functional class II) on angiotensin-converting enzyme inhibi-
tor, beta-blocker, and diuretic therapy.
The INLVM-17 is a 33-year-old male, diagnosed with
DCM at 30 years of age during a family echocardiographic
screen after sudden death occurred within the family.
Echocardiographic and MRI screening identified both left
and right ventricular trabeculations, with an intraventricular
conduction delay and ventricular bigeminy on electrocar-
diogram, as well as echocardiographic evidence of bor-
derline systolic function and a dilated left ventricle. In the
other family members, neither DCM nor INLVM was
identified.
Sequence analysis identified a G349A mutation (Fig. 5A)
in exon 6 of both patients, resulting in an amino acid change
from the acidic aspartic acid to the neutral, polar asparagine
at position 117 (D117N) in Cypher/ZASP1, -2, and -3
(Fig. 1B), and predicted to result in the suppression of four
-helices at residues 202, 229, 268, and 274, respectively
(data not shown). Aspartic acid 117 is conserved in mouse
and rat, while it is glutamic acid in Xenopus laevis and
zebrafish.
PATIENT DCM-31. A further abnormal DHPLC pattern was
identified in exon 6 in proband DCM-31, a 16-year-old
Caucasian male referred to us from an outside institution
and diagnosed with DCM by echocardiography. The DNA
sequence analysis identified an A407T mutation (Fig. 5B)
that changes the basic lysine to neutral, non-polar methio-
nine at position 136 (K136M) in Cypher/ZASP1, -2, and
-3 (Fig. 1B), and predicted to result in the loss of an -helix
at residue 202 and the creation of a -helix at residue 246
(data not shown). The K136 residue is highly conserved in
species ranging from human to Xenopus leavis.
The DNA was obtained from the parents, after informed
consent, and the sequence analysis did not reveal the same
change, consistent with a de novo mutation.
Genetic polymorphisms in DCM and INLVM. Another
abnormal DHPLC pattern was identified in exon 7 in four
probands with DCM, three Caucasians and one Asian, as
well as one African-American proband with INVLM. The
DNA sequence analysis identified an A612G mutationTa
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(data not shown), which changes the basic amino acid lysine
to the basic amino acid arginine at position 204 (K204R) in
Cypher/ZASP1, -2, and -3 (position 251 in isoform 4 and
position 319 in isoform 5 and 6) (Fig. 1B). This substitution
was not found in 200 Caucasian, 200 Hispanic, and 200
Asian controls, but was identified in 6 of 100 African-
American subjects, suggesting K204R is a modifier or
polymorphism, rather than a disease-causing mutation.
Myocardial expression of Cypher/ZASP. We investigated
the cardiac expression of each exon where Cypher/ZASP
mutations were identified by RT-PCR and Northern blot
analysis (Fig. 6). The detection of exons 2 and 7, present
in all Cypher/ZASP isoforms, confirms that Cypher/ZASP
is expressed in human heart. Exons 4 (C/Z4-6), 5 and 6
(C/Z1-3), and 10 (C/Z2 and 4) were detected (Fig. 6A),
demonstrating the expression of these exons in human
heart, and supporting a functional role of the mutations
in cardiac disease. In addition, a strong signal was
detected for exon 9 by for Northern blot analysis of
human cardiac RNA, suggesting a high expression of
isoforms C/Z1 and 6 (Fig. 6B). Sequencing analysis
confirmed that the RT-PCR products were the expected
Cypher/ZASP products.
Cypher/ZASP expression in transfected cells. Expression
of GFP following transient transfection of non-
differentiated C2C12 cells with the pcDNA 3.1/NT-GFP-
TOPO vector did not disrupt the actin cytoskeleton (Fig.
7A): GFP was distributed homogeneously throughout the
cell (Fig. 7B). Expression of the wt-Cypher/ZASP-GFP
fusion protein in non-differentiated C2C12s showed that
Cypher/ZASP co-localizes with the intact actin cytoskeletal
network (Figs. 7D to 7F). In contrast, in cells transfected
with D117N-Cypher/ZASP, abnormal Cypher/ZASP and
actin staining were observed, with disarray of the actin
cytoskeleton in both (Figs. 7G to 7I).
Western blot analysis demonstrated that both wt-Cypher/
ZASP and D117N-Cypher/ZASP were found exclusively in
the insoluble fraction, and their expression levels were
comparable (Fig. 8).
DISCUSSION
Over the last several years, the genetic basis of DCM has
begun to be elucidated with the identification of several
disease-causing genes. The mutant proteins have been
shown to be involved in an apparent “final common path-
way” (33), which links the extracellular matrix to the
sarcolemma, sarcomere, and nuclear membrane. These
genes include dystrophin, G4.5, lamin A/C, desmin, actin,
-sarcoglycan, -sarcoglycan, -myosin heavy chain, cardiac
troponin T, -tropomyosin, titin, vinculin, muscle LIM pro-
tein, and phospholamban for “pure” DCM or conduction
system disease associated with DCM (CDDC) (9,20–22).
In addition, mutations in -dystrobrevin and G4.5 have
been shown to cause DCM associated with INLVM (24).
Cypher/ZASP is a novel cardiac and skeletal muscle-
specific Z-line protein (28) that is expressed in the cyto-
plasm, co-localizing with actin. The protein contains a PDZ
domain that interacts with the C-terminus of -actinin-2
(28). The PDZ domain-containing proteins interact with
each other in cytoskeletal assembly or with proteins involved
in targeting and clustering of membrane proteins (34,35). A
Cypher knockout mouse develops a severe congenital myop-
athy and dilated cardiomyopathy (36). Thus, we speculated
that Cypher/ZASP could have an important role in the
maintenance of the normal cytoarchitecture, and as such
would be a candidate gene for DCM with or without other
abnormalities, such as INLVM.
To assess the role of Cypher/ZASP in human cardiac
diseases, we characterized the genomic structure of human
Cypher/ZASP, identifying 16 coding exons and the exon-
intron boundaries as well as the exon composition of each of
the major isoforms.
Four major human Cypher/ZASP isoforms were originally
described: ZASP, ZASPV2, ZASPV3, and KIAA0613-like
(28). Here, we refer to the ZASP, ZASPV3, and KIAA0613-
Figure 6. Analysis of the expression of Cypher/ZASP isoforms in human
heart. The Cypher/ZASP exons were detected in human cardiac ribonucleic
aid by reverse transcription-polymerase chain reaction (A) and Northern
blot analysis (B). The exons identified are shown at the bottom of each
panel. M  100 bp deoxyribonucleic acid ladder (A). Positions of
ribonucleic acid size markers are indicated (B).
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like variants as to Cypher/ZASP1, -3, and -4, respectively. In
addition, three other isoforms have been identified in mice
and humans. These are referred to as Cypher/ZASP2, -5,
and -6 (Fig. 1A). We have been unable to identify the
isoform ZASPV2.
The functional significance of the various isoforms is
unknown, although their structure, either containing only
the PDZ domain (Cypher/ZASP1) or containing both
PDZ and LIM domains (Cypher/ZASP2-5), leads to the
hypothesis of multiple functions, like other proteins that
have similar domain arrangements, such as the muscle LIM
protein (37).
We screened subjects with familial or sporadic forms of
DCM, as well as patients with INLVM with hypertrophy,
dilation, and systolic dysfunction. We identified five Cypher/
ZASP mutations in 6 of 100 probands screened (6% of
cases), including two familial cases and four sporadic cases.
None of the mutations were identified in 400 chromosomes
from ethnic-matched controls, and all resulted in altered
conserved amino acids, suggesting their functional importance.
In mice, isoforms containing exon 6 were highly ex-
pressed in skeletal muscle, but were not detectable in the
heart by Western blot analysis (38). Here we have demon-
strated that the domain encoded by exon 6 of human
Cypher/ZASP, which encodes the D117N and K136M
mutations, is expressed in human heart as detected by both
Northern and Western blot analyses. Consistent with our
results in humans, prolonged exposure times of both North-
ern and Western blots of extracts from mouse heart have
revealed low levels of expression of Cypher isoforms con-
taining exon 6 (Huang and Chen, personal communica-
tion, 2003). In addition, three of the Cypher/ZASP muta-
tions are encoded by exons 4 (T213I, S196L) and 10
(I352M), which are present in Cypher/ZASP2 and -4
isoforms whose expression in the human heart was previ-
ously unknown (28). Here we demonstrate that both exons
4 and 10 are expressed in the human heart, supporting the
functional significance of these mutations in left ventricular
dysfunction.
Figure 7. Immunohistochemical analysis of Cypher/ZASP expression. Immunohistochemical analysis of C2C12 cells transfected with the pcDNA3.1/NT-
GFP-TOPO vector (A to C), or with constructs expressing wild type Cypher/ZASP-1-GFP (D-F) or D117N-Cypher/ZASP-1-GFP (G to I). Actin
staining (red) is shown in the left panels, GFP (Cypher/ZASP ) staining (green) is shown in the middle panels, while the right panels are the overlay of
the ZASP, actin and DAPI (nuclei) images. All images were obtained using 40 magnification.
Figure 8. Western blot analysis of ZASP expression. Western blot analysis
of protein isolated from C2C12 cells transfected with wild type (lanes 1
and 3), D117N (lanes 2 and 4) Cypher/ZASP, separated into insoluble (IF)
and soluble (SF) fractions.
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The I352M mutation was found in a family with “pure”
DCM, where the proband and his offspring presented with
typical DCM, but with phenotypic variability, while
K136M was found in a sporadic DCM patient. However,
the other mutations were found in individuals diagnosed
with INLVM associated with left ventricular dilation and
systolic dysfunction. Family 065, carrying the S196L mu-
tation, showed a particularly malignant form in the mother
and the brother of the proband, although the niece of the
proband has a milder phenotype; however, this may be a
function of age. The T213I mutation identified in sporadic
case, DCM/INLVM 035, results in mild left ventricular
dysfunction, but was associated initially with severe conduc-
tion disturbances, whereas the D117N mutation was asso-
ciated with severe left ventricular dilation and the occur-
rence of particularly malignant rhythm abnormalities
(Patients INLVM-11 and INLVM-17).
Although no phenotype-genotype correlation can be
made at this stage of the study, it is interesting that
mutations in exon 4 (S196L and T213I) lead to INLVM,
suggesting a role for this domain in normal left ventricular
morphogenesis and contractile function. Mutations D117N
and K136M, encoded by exon 6, lead to INLVM and
DCM, respectively, suggesting a more complex role for this
domain. The mutation encoded by exon 10 (I352M) is
associated with “pure” DCM in contrast to the other
Cypher/ZASP4 mutations (S196L and T213I). Targeted
protein-protein interaction analysis of these specific por-
tions of Cypher/ZASP may explain the clinical heteroge-
neity.
At the time, complementary DNA clones of the exon 4
containing isoforms were not available and, therefore, our
functional studies have been focused on the D117N muta-
tion, encoded by exon 6. We hypothesized that expression
of mutated Cypher/ZASP could affect the stability of actin
cytoskeletal network, as well as its connection to the cell
membrane. This was confirmed by the observation that in
cells expressing the D117N mutation, the Cypher/ZASP
mutation resulted in disarray of the actin cytoskeleton. We
speculate that D117N affects Cypher/ZASP binding to
proteins interacting with the actin network, such as
-actinin-2. Studies are underway to prove this hypothesis and
to determine whether D117N alters the Cypher/ZASP sec-
ondary structure, thereby impairing the -actinin-2 binding
site, modifying Cypher/ZASP anchorage to the sarcomeric
compartment, or whether it causes an indirect modification in
the tertiary structure of the actin-binding site of -actinin-2.
In conclusion, we have identified a new gene causing both
the “pure” form of DCM and DCM associated with
INLVM. This gene, Cypher/ZASP, encodes a specific
Z-line PDZ-domain protein, playing a potential important
role in bridging the sarcomere to the cytoskeletal network.
Description of multiple mutations in Cypher/ZASP in pa-
tients with DCM and INLVM suggests that disruption of
this gene is a common cause of left ventricular dysfunction
and dilation, and it provides further support for the concept
that disruption of the cytoarchitecture, comprising the
cytoskeleton, sarcolemma, sarcomere, and interacting com-
ponents is pivotal to the development of left ventricular
dysfunction. Although all the patients with Cypher/ZASP
mutation had normal creatine kinase levels and muscle
function, mutations that were identified in Cypher/ZASP
isoforms and expressed in skeletal muscle leads to the
possibility that Cypher/ZASP mutations are responsible for
skeletal muscle abnormalities associated with heart failure
(such as fatigue and exercise intolerance), as has been
described for patients with - and -sarcoglycan, dystrophin,
G4.5, desmin, and lamin A/C mutations (9,39). The common
frequency of mutations in this gene and its interactions with
other proteins of the actin cytoskeleton shown to cause left
ventricular dysfunction suggest that this component of the
heart and skeletal muscle is important in functional integ-
rity.
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